Noveome Biotherapeutics
PrivateLast Round
Seed Round
Aug 27, 2026
Total Funding Raised
$185.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Noveome Biotherapeutics is a biotechnology company that develops novel biotherapeutic products aimed at treating inflamed or damaged tissues through a synergistic combination of biologic components.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Noveome Biotherapeutics Comparables
Compare Noveome Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Secretome Therapeutics | 85% | |
| Plakous Therapeutics | 82% | |
| Direct Biologics | 81% |
Noveome Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Aug 27, 2026 | ||||
| Series E | Apr 23, 2025 | ||||
| Grant | Jun 23, 2021 | ||||
| Grant | May 7, 2020 | ||||
| Series D | Apr 9, 2019 | ||||
Grant | Apr 3, 2018 |
Key People
Founding team and executive leadership
Noveome Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| University of Pittsburgh Investment Office | Seed |
| Carnegie Mellon University Investment Office | Seed |
| Miraki | Series E |
| U.S. Department of War | Grant |
| Commonwealth of Pennsylvania | Grant |
| MAK Capital One | Series E |
| Lancet Capital | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 27, 2026
Raised $7M in a Seed Round.
- Apr 23, 2025
$51M round led by MAK Capital One.
Recent news
Latest coverage and updates
- is_developingJun 15, 2026
Noveome Biotherapeutics, Inc. is developing ST266 on Jun 15th '26.
Noveome Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Noveome Biotherapeutics's valuation, stock price, and market status.
Is Noveome a public or private company?
Noveome is a private company.
What is the current stock price of Noveome?
Noveome is a private company with no public stock price. No recent secondary market data is available.
How much is Noveome worth (valuation)?
Valuation information for Noveome is not publicly available.
Can I buy Noveome stock?
Noveome shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Noveome's last funding round?
Noveome's most recent funding round was Series E on April 23, 2025.
Who are the main investors in Noveome?
Key investors in Noveome include MAK Capital One, Lancet Capital.
Will Noveome IPO soon?
No public IPO plans have been announced for Noveome.
How can I track Noveome secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Noveome's secondary market activity and sign up for updates.